Anders Mainz ApS specializes in sustainable construction and renovation using breathable and bio-based materials, focusing on improving indoor climate and providing economically sustainable solutions.

Anders Mainz ApS

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

Google Tag Manager

Apple Mobile Web Clips Icon

Google Analytics

DNSSEC

Content Delivery Network

WordPress

Global Site Tag

Chief Executive Officer

Guido Baechler

VP of Clinical Affairs

Jane Edwards

Director of Regulatory Affairs

Amy Levin

Clinical Trial Manager

Lara Rohwer

Logistics & Facility Manager

Vadym Ismailov

Chief Operating Officer

Chris von Toerne

Consultant

Niamh Nolan

Chief Executive Officer & Director

Darin Leigh

Chief Commercial Officer

Steve Quinn

Vice President Business Development

Vice President of Regulatory Affairs

Karen Richards

VP of Regulatory Affairs

Tarrin Khairi-Taraki

Vice President of Commercial Operations

Health Diagnostics Companies With Fewer Than 100 Employees (Top 10K)

Europe, Middle East, and Africa (EMEA) Health Diagnostics Companies

Mainz Companies

Europe Public Companies With More Than 50 Employees

Mainz BioMed primarily operates as a molecular genetic diagnostics company. It develops market-ready molecular genetic diagnostic solutions for life-threatening conditions.

Post-IPO Equity - Mainz Biomed

Computer and Software Products and Electrical and Scientific Products

Mainz

Rheinland-Pfalz

Germany

Europe

Mainz Biomed

Other news to note for November 13, 2024

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets

Mainz Biomed and Thermo Fisher Scientific Sign a Collabor...

In Brief This Week: Mainz Biomed, Evotec, Hologic, Proteomics International, PacBio, More

Mainz Biomed Reports Mid-Year 2024 Financial Results and...

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edg...

Mainz Biomed seeks FDA’s Breakthrough Devices Designation for advanced colorectal cancer test

Mainz Biomed requests breakthrough device designation from FDA for CRC product

Mainz Biomed Provides Half Year 2024 Corporate Update

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

A non-invasive, at-home colorectal cancer screening test that uses PCR technology to detect tumor DNA in stool samples, offering higher sensitivity and specificity compared to traditional fecal tests.

A multimodal screening test combining Fecal Immunochemical Test (FIT), mRNA biomarkers, and AI algorithms to differentiate between colorectal cancer, advanced adenomas, and non-advanced adenomas.

An early-stage pancreatic cancer screening test currently in development.

An FDA PMA pivotal study aimed at gaining approval for Mainz Biomed's next-generation colorectal cancer screening test in the US and its international market launch.

United States

North America

United Kingdom

Canada

Ukraine

HTML5

Facebook Comments

Gravity Forms

Adobe Fonts

Vimeo

jQuery

Wordpress

Google Fonts

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 17, 2024 2:45 PM	2a9d77db
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 17, 2024 2:45 PM	b9e67e90
crunchbase trigger	general	Nov 17, 2024 2:45 PM	dd79e26c
crunchbase profile	general	Nov 17, 2024 2:51 PM	7242a972
li profile	general	Nov 17, 2024 2:45 PM	1717d4e4
translate crunchbase fundingrounds	general	Nov 17, 2024 3:20 PM	88a48f8b
peers	general	Nov 17, 2024 2:45 PM	7c898087
news basic	general	Nov 17, 2024 2:45 PM	067560b9
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

MAIN

DK:MAINZ

Anders Mainz ApS